SCHEMBL4332747

SCHEMBL4332747

CCOC(=O)c1[nH]c2ccccc2c1N

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 13/20 0.70
ALDH1A1 P00352 6/20 0.70
GAA P10253 3/20 0.70
MAPT P10636 3/20 0.70
RAB9A P51151 2/20 0.70
SMN1; SMN2 Q16637 2/20 0.70
NPC1 O15118 1/20 0.70
TP53 P04637 1/20 0.70
HTR6 P50406 2/20 0.67
TUBB4A P04350 2/20 0.61
TUBB P07437 2/20 0.61
TUBA3C P0DPH7 2/20 0.61
TUBA1B P68363 2/20 0.61
TUBA4A P68366 2/20 0.61
TUBB4B P68371 2/20 0.61
TUBB3 Q13509 2/20 0.61
TUBB2A Q13885 2/20 0.61
TUBB8 Q3ZCM7 2/20 0.61
TUBA3E Q6PEY2 2/20 0.61
TUBA1A Q71U36 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8801503 0.98 KDM4E (0.68) KDM4EALDH1A1GAAMAPTRAB9A
SCHEMBL13758171 0.86 KDM4E (0.60) KDM4EALDH1A1GAAMAPTRAB9A
SCHEMBL2880010 0.84 KDM4E (0.66) KDM4EALDH1A1GAAMAPTRAB9A
SCHEMBL28746471 0.84 KDM4E (0.82) KDM4EALDH1A1GAAMAPTRAB9A
SCHEMBL3276393 0.83 TUBB4A (0.67) KDM4EALDH1A1GAAMAPTRAB9A
SCHEMBL7534562 0.83 ALDH1A1 (0.71) KDM4EALDH1A1GAAMAPTRAB9A
SCHEMBL24487443 0.83 HTR6 (0.61) KDM4EALDH1A1GAAMAPTRAB9A
SCHEMBL5220303 0.83 KDM4E (0.66) KDM4EALDH1A1GAAMAPTRAB9A
SCHEMBL31019418 0.83 KDM4E (0.66) KDM4EALDH1A1GAAMAPTRAB9A
SCHEMBL14174308 0.83 ALDH1A1 (0.60) KDM4EALDH1A1GAAMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282786-A1 Tricyclic TLR7 Agonists and Uses Thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2025-09-11 US disclosed
WO-2024238359-A2 TARGETING RNAS ASSOCIATED WITH TAUOPATHIES WITH SMALL MOLECULES UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2024-11-21 WO disclosed
WO-2017163263-A1 INDOLE DERIVATIVES, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-09-28 WO disclosed
US-9505768-B2 Compositions and methods for modulating TLR4 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-11-29 US disclosed
US-9505768-B2 Compositions and methods for modulating TLR4 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-11-29 US disclosed
US-9505768-B2 Compositions and methods for modulating TLR4 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-11-29 US disclosed
EP-3046156-A1 ORGANIC ELECTROLUMINESCENT ELEMENT, AND ILLUMINATION DEVICE AND DISPLAY DEVICE EACH COMPRISING THE ELEMENT Konica Minolta Holdings, Inc. (JP) 2016-07-20 EP disclosed
US-20150197527-A1 COMPOSITIONS AND METHODS FOR MODULATING TLR4 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2015-07-16 US disclosed
US-20150197527-A1 COMPOSITIONS AND METHODS FOR MODULATING TLR4 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2015-07-16 US disclosed
US-20150197527-A1 COMPOSITIONS AND METHODS FOR MODULATING TLR4 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2015-07-16 US disclosed
EP-0741711-A1 TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY WARNER-LAMBERT COMPANY (US) 1996-11-13 EP disclosed
WO-1996022992-A1 TRICYCLIC SUBSTITUTED HEXAHYDROBENZ[E]ISOINDOLE ALPHA-1 ADRENERGIC ANTAGONISTS ABBOTT LABORATORIES (US) 1996-08-01 WO disclosed
US-5491153-A 3-amidoindolyl derivative MERRELL DOW PHARMACEUTICALS INC. (US) 1996-02-13 US disclosed
US-5463054-A Diagnosis and treatment of anxiety, sleep, seizure disorders, overdose with benzodiazepine drugs, enhancement of memory NEUROGEN CORPORATION (US) 1995-10-31 US disclosed
WO-1995019970-A1 TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY WARNER-LAMBERT COMPANY (US) 1995-07-27 WO disclosed
WO-1994025463-A1 CERTAIN ARYL FUSED PYRROLOPYRIMIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 1994-11-10 WO disclosed
US-5328920-A Alleviating memory dysfunctions HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1994-07-12 US disclosed
US-5326868-A Treatment of sleep disorders, anxiety, seizures, memory NEUROGEN CORPORATION (US) 1994-07-05 US disclosed
US-5189054-A 3-amidoindolyl derivatives and pharmaceutical compositions thereof MERRELL DOW PHARMACEUTICALS INC. (US) 1993-02-23 US disclosed
EP-0483881-A1 3-Amidoindolyl derivatives MERRELL PHARMACEUTICALS INC. (US) 1992-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282786-A1 Tricyclic TLR7 Agonists and Uses Thereof TLR7, TLR9, TLR1 KDM4E 3303/4885ALDH1A1 2553/4885GAA 2101/4885
US-20150197527-A1 COMPOSITIONS AND METHODS FOR MODULATING TLR4 TLR4, TLR3, TLR6 KDM4E 1323/4885ALDH1A1 4647/4885GAA 4499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.